Simeprevir

Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.

Also Known As:

N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide; Olysio; TMC 435; TMC 435350; TMC-435; TMC-435350; TMC435; TMC435350; 435, TMC; 435350, TMC

Networked: 352 relevant articles (48 outcomes, 87 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lenz, Oliver: 20 articles (01/2018 - 03/2010)
2.	Peeters, Monika: 18 articles (01/2017 - 01/2011)
3.	Ouwerkerk-Mahadevan, Sivi: 15 articles (01/2019 - 06/2014)
4.	Scott, Jane: 12 articles (01/2019 - 12/2013)
5.	Zeuzem, Stefan: 10 articles (01/2019 - 06/2012)
6.	Vijgen, Leen: 9 articles (06/2020 - 05/2015)
7.	Fevery, Bart: 9 articles (01/2019 - 11/2014)
8.	Kalmeijer, Ronald: 9 articles (01/2019 - 06/2014)
9.	Moreno, Christophe: 9 articles (01/2019 - 01/2011)
10.	Beumont, Maria: 8 articles (06/2020 - 08/2014)

Related Diseases

1.	Infections 01/01/2017 - "The Simeprevir ObservatioNal Effectiveness across practice seTtings (SONET) study evaluated the real-world effectiveness of simeprevir-based treatment for hepatitis C virus (HCV) infection. " 01/01/2017 - "This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simeprevir plus PR in 67 patients with HCV GT4 infection. " 02/01/2014 - "Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial." 12/01/2013 - "The authors present: i) an overview of Phases I - III clinical trials of simeprevir for HCV infection based on peer-reviewed literature and congress presentations and ii) an evaluation of the efficacy and safety of simeprevir in the treatment of HCV infection. " 12/01/2019 - "Unexpectedly, our current work discovered that Simeprevir effectively promoted the transcription of IFN-β and ISG15, inhibited the infection of host cells by multiple viruses including Zika virus (ZIKV), Enterovirus A71 (EV-A71), as well as herpes simplex virus type 1 (HSV-1). "
2.	Fibrosis (Cirrhosis) 01/01/2017 - "Simeprevir-based treatment was effective and well tolerated in this cohort, including patients with cirrhosis." 01/01/2016 - "This observation, along with similar cases recently reported in the literature, should raise awareness of the potential for decompensation in patients with advanced cirrhosis treated with simeprevir. " 04/01/2015 - "Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis." 07/01/2014 - "In patients with cirrhosis or extrahepatic manifestations of HCV who cannot tolerate PEGINF, we use 12 weeks of SOF and simeprevir. " 01/01/2011 - "Treatment-experienced patients (n=37; 56.8% with cirrhosis) received 75, 150 or 200 mg TMC435 once daily, or placebo with P/R for 28 days. "
3.	Hepatitis C 02/01/2015 - "[Pharmacological properties of simeprevir (SOVRIAD® capsules 100 mg), a new drug for the treatment of hepatitis C, and results of its clinical studies]." 06/02/2020 - "Simeprevir is one of the newest direct action anti-hepatitis C drugs. " 07/01/2018 - "Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study." 01/01/2017 - "Mucocutaneous toxicity during simeprevir treatment for hepatitis C. " 07/01/2016 - "Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C treatment protocol. "
4.	Chronic Hepatitis C 01/01/2017 - "Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study." 06/01/2017 - "Up till now the role of simeprevir plasma concentrations has not been described in treated patients affected by chronic hepatitis C and with dermatological side-effects. " 01/21/2015 - "Simeprevir received its first global approval in Japan in September 2013 for the treatment of genotype 1 chronic hepatitis C in combination with PEG-IFN and RBV. " 01/01/2014 - "New treatments for genotype 1 chronic hepatitis C - focus on simeprevir." 12/01/2013 - "This article summarizes the milestones in the development of simeprevir leading to this first approval for chronic hepatitis C. "
5.	Liver Diseases (Liver Disease) 05/01/2016 - "This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha-2a and ribavirin (PR) in HCV GT1-infected, treatment-naïve, Asian patients with compensated liver disease. " 01/01/2017 - "Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease." 12/01/2015 - "Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease. " 03/01/2015 - "PubMed for 2004 through August 2014 using search terms hepatitis C, American Association for the Study of Liver Diseases, sofosbuvir, simeprevir, and as needed specific names of other agents in development during this time; news articles and news releases about company actions with regard to clinical trials and filings for marketing approval in the United States. " 01/01/2017 - "We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment-naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients with pre-defined NS5A resistance-associated substitutions. "

Related Drugs and Biologics

1.	Sofosbuvir
2.	Ribavirin (Virazole)
3.	daclatasvir
4.	Interferons
5.	Antiviral Agents (Antivirals)
6.	sofosbuvir drug combination ledipasvir
7.	telaprevir
8.	paritaprevir
9.	ombitasvir
10.	ledipasvir

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Aftercare (After-Treatment)
4.	Oral Administration
5.	Duration of Therapy